Impact of Treatment Strategies on Local Control and Survival in Uterine Carcinosarcomas in Turkey

Abstract

Background: The purpose of this study was to determine the clinical characteristics, patterns of recurrence and survival outcomes in patients with uterine carcinosarcomas treated in our institution. Materials and Methods: Records of 26 patients diagnosed between 2007 and 2011 with uterine carcinosarcoma were retrospectively evaluated for demographic features, tumor characteristics, treatment regimens and patient outcomes in terms of DFS and OS Results: Median age was 61 (range 43-78). 10 patients (38%) had stage I disease at diagnosis, 3 (12%) had stage II, 4 (15%) had stage III and 9 (35%) had stage IV. Sixteen patients (62%) received chemotherapy with paclitaxel and carboplatin for 6 cycles. One patient underwent radiotherapy. Median follow up was 17 months. Sixteen patients relapsed and 13 died during follow up. Considering recurrence, 5 out of 16 patients had lung metastases, one had brain metastases and 9 had only intraabdominal recurrence. The 3 year DFS was 37% and the 3 year OS was 30%. Conclusions: Our data show that uterine carcinosarcomas tend to be at advanced stage at diagnosis and despite the use of chemotherapy, overall prognosis is poor. Surgery remains the mainstay of treatment. More effective adjuvant strategies are needed to reduce relapse and death rates.

Clinical Outcomes of Uterine Carcinosarcoma

“…Reported 2-year DFS and 2-year OS ranged between 26% to 58% and 48% to 64%, respectively. 17,18 These rates were reported 27% for 5-year DFS and 30% to 60% for 5-year OS. 18Y20 In this study, 3-year DFS and 3-year OS were 42.7% and 59.2%, respectively.…”

Clinical Study on Carboplatin for Treating Pediatric Patients with Wilms Tumors

“…It was reported that the response rate of children with relapsed or resistant WT to a combination of carboplatin, ifosfamide, and etoposide, at the maximal tolerated dose of 635 mg/m 2 for carboplatin, is associated with a CR rate of 32% and a total response rate of 63% (Kung et al, 1993;Kung et al, 1995). In the field of cancer chemotherapy including in the treatment of WT, carboplatin is a common choice (Akkuzu et al, 2013;Bag et al, 2013;Butthongkomvong et al, 2013;Fu et al, 2013;Khemapech et al, 2013;Kucukoztas et al, 2013;Natukula et al, 2013;Oranratanaphan et al, 2013;Ozdemir et al, 2013;Zhang et al, 2013;Pitakkarnkul et al, 2013). It was reported that carboplatin, at a dose of 550 mg/m 2 every 3 weeks, as a single drug resulted in a response rate of 53% in children with relapsed WT (de Camargo et al, 1994).…”